Apyx Medical (NASDAQ:APYX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Apyx Medical (NASDAQ:APYX) posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04, Morningstar.com reports. The business had revenue of $5.82 million during the quarter. Apyx Medical had a negative return on equity of 12.25% and a net margin of 224.06%.

APYX stock opened at $6.03 on Friday. Apyx Medical has a twelve month low of $3.55 and a twelve month high of $8.89. The firm has a market capitalization of $210.38 million, a price-to-earnings ratio of -20.79 and a beta of 0.24.

A number of research firms have recently commented on APYX. Zacks Investment Research downgraded Apyx Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 18th. JMP Securities decreased their price target on Apyx Medical from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Tuesday, April 2nd. TheStreet lowered Apyx Medical from a “c-” rating to a “d” rating in a report on Monday, May 20th. Piper Jaffray Companies decreased their price target on Apyx Medical to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, May 8th. Finally, ValuEngine upgraded Apyx Medical from a “buy” rating to a “strong-buy” rating in a report on Monday, April 29th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $8.00.

A number of hedge funds have recently added to or reduced their stakes in APYX. Tibra Equities Europe Ltd bought a new stake in Apyx Medical during the first quarter valued at about $369,000. Nkcfo LLC bought a new stake in Apyx Medical during the first quarter valued at about $96,000. Perkins Capital Management Inc. bought a new stake in Apyx Medical during the first quarter valued at about $1,549,000. Creative Financial Designs Inc. ADV bought a new stake in Apyx Medical during the first quarter valued at about $380,000. Finally, Bailard Inc. bought a new stake in Apyx Medical during the first quarter valued at about $99,000. Institutional investors and hedge funds own 47.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first published by Rockland Register and is the sole property of of Rockland Register. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://rocklandregister.com/2019/06/01/apyx-medical-apyx-issues-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

About Apyx Medical

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Recommended Story: What Factors Can Affect Return on Equity?

Earnings History for Apyx Medical (NASDAQ:APYX)

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.